Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zhejiang Hisun Partners with Seattle's IDRI on Treatment for Drug-Resistant TB

publication date: Aug 25, 2017

Zhejiang Hisun Pharma will provide clinical trial supplies of a novel inhaled treatment for drug resistant TB for Seattle's IDRI (Infectious Disease Research Institute). The agreement, described as a partnership, will presumably include commercial supply, though details were not disclosed. CPZEN-45 was originally discovered by the Institute of Microbial Chemistry (IMC), a nonprofit Tokyo research institute. It has reached late pre-clinical development through work done at the IDRI and the Lilly TB Drug Discovery Initiative, which is focused on finding effective treatments for drug-resistant TB. More details....

Stock Symbol: (SHA: 600267)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.